Sagimet Biosciences CEO David Happel Executes Mandatory Share Sale Amid Strategic Pivot
Sagimet Biosciences Inc. (NASDAQ: SGMT) reported that President, CEO, and Director David Happel sold 64,051 shares of Series A Common Stock on July 20, 2026. The transaction, valued at $497,067, was a mandatory sale designed to satisfy tax withholding requirements associated with the vesting of restricted stock units. This automatic, non-discretion…